# LIFT: Life Improvement Trial

> **NCT06366724** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 160 (estimated)

## Conditions studied

- ME/CFS
- Long COVID
- PASC

## Interventions

- **DRUG:** Pyridostigmine
- **DRUG:** Low-Dose Naltrexone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06366724
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06366724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06366724, "LIFT: Life Improvement Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06366724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*